7月26日，K药登陆中国。此后随着K药——帕博利珠单抗（Pembrolizumab）等免疫抑制剂在国内的陆续上市，我国已进入免疫治疗新时代。免疫检查点抑制剂不仅颠覆了肺癌等多种癌症的治疗理念，更为癌症治疗带来新方向和希望。帕博利珠单抗是FDA批准的首款不依照肿瘤来源，而依照生物标志物进行区分的抗肿瘤疗法，是第一个真正意义上的广谱抗癌药。它已经在全球80多个国家获批试用，覆盖了9个瘤种的12个以上适应症，包括黑色素瘤、非小细胞肺癌、头颈癌、霍奇金淋巴瘤、膀胱癌、宫颈癌、胃癌、B细胞淋巴瘤等。帕博利珠单抗能快速获批，在循证学方面很大程度上依赖于KEYNOTE系列临床研究，如在4月，KEYNOTE-042研究数据公布后数日，FDA便批准了帕博利珠单抗单抗作为单药一线治疗PD-L1阳性（PD-L1表达肿瘤比例评分TPS＞1%）局部晚期/转移性非小细胞肺癌患者。为此，AME出版社针对KEYNOTE系列临床试验，邀请国际范围内的各学科顶尖专家对KEYNOTE相关研究展开述评，以期进一步讨论、推动癌症的免疫治疗，使患者受益。截止目前，我们已收到来自全球各国超过60篇的优质述评稿件，并已上线50余篇稿件。为使国内同行更高效获取此系列研究，现拟开展第二批译者招募。根据稿件上线情况和后续约稿，我们还将开展第三批译者招募，敬请期待！
待翻译文章列表：
Immunotherapy for mucosal melanoma
Immunotherapy in EGFR mutant non-small cell lung cancer: when, who and how?
The KEY to the end of the chemotherapy in advanced non-small cell lung cancer, ornot yet?
First-line immunotherapy for patients with advanced stage or metastatic non-small cell lung cancer…finally what threshold of PD-L1 expression on tumor cells?
Can PD-L1 tumor proportion score be used as the key to unlocking the KEYNOTE studies of pembrolizumab in advanced lung cancer?
Extended follow-up on KEYNOTE-024 suggests significant survival benefit for pembrolizumab in patients with PD-L1 ≥50%, but unanswered questions remain
Pembrolizumab monotherapy for PD-L1 ≥50% non-small cell lung cancer, undisputed first choice?
Pembrolizumab plus ipilimumab or pegylated interferon alfa-2b for patients with melanoma or renal cell carcinoma: take new drugs but keep the old?
KEYNOTE-042: is lowering the PD-L1 threshold for first-line pembrolizumab monotherapy a good idea?
First-line pembrolizumab in programmed death ligand 1 positive non-small cell lung cancer
Pembrolizumab monotherapy in advanced NSCLC patients with low PD-L1 expression: is there real evidence?
Immune checkpoint inhibitors for esophageal cancer: are we moving in the right direction?
Pembrolizumab plus axitinib: a new treatment option for patients with metastatic renal cell carcinoma
认领方法：
